
FDA updates MYQORZO label with Phase 3 data showing it outperforms beta-blocker metoprolol in treating oHCM.
Cytokinetics announced FDA approval to update MYQORZO's prescribing information to include Phase 3 MAPLE-HCM trial data comparing MYQORZO (aficamten) to the beta-blocker metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (o...

